Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezagitamab in adults with chronic primary immune thrombocytopenia
2024-514401-54-00Phase 3Authorised
- Sponsor
- Takeda
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in chronic primary immune thrombocytopenia (ITP) comparing Mezagitamab with Placebo matching for mezagitamab (2 arms). Primary endpoint: Durable platelet response through Week 24. Planned start Nov 2025; status: authorised.
02
Drugs
mezagitamab
03
Conditions
chronic primary immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2024-514401-54-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514401-54-00.